Filing search / Kineta, Inc. / "Demographics"

8-K

EX-99.2

KANT Kineta, Inc.

12 Mar 24

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

8:05am

(0) 2 (40) 7 (26) VISTA-101: Demographics As of 02/27/24 VISTA-101: KVA12123 was well tolerated in 3, 10, 30, 100 and 300mg monotherapy cohorts

8-K

EX-99.1

KANT Kineta, Inc.

5 Jan 24

Regulation FD Disclosure

4:30pm

Antineoplastic surgery 11 (73) 15 (100) 13 (87) Baseline ECOG N (%) Grade 0 Grade 1 3 (20) 12 (80) Demographics Stage and prior treatments Patients

8-K

EX-99.2

KANT Kineta, Inc.

6 Nov 23

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

8:30am

Antineoplastic medication Antineoplastic surgery 9 (82) 11 (100) 11 (100) Baseline ECOG N (%) Grade 0 Grade 1 2 (18) 9 (82) Demographics Stage and prior

8-K

EX-99.1

KANT Kineta, Inc.

10 Nov 21

Regulation FD Disclosure

7:12am

occurred in the study 20 Patient Baseline Characteristics Variable Placebo (n=4) YTX-7739 (n=16) Demographics Males/Females Mean Age (min-max) Mean

8-K

EX-99.1

KANT Kineta, Inc.

5 Mar 20

Regulation FD Disclosure

4:30pm

(12.0) 62.8 (7.9) Baseline Demographics and Clinical Characteristics of F508del Homozygous and Heterozygous Study Cohorts 7 F508del Homozygous F508del

8-K

EX-99.2

gix2ehlz1u pty

22 Jan 20

Proteostasis Therapeutics Announces Keystone Symposia Presentation of

7:00am

8-K

EX-99.2

8vyxwwap zztfamxp

17 Dec 19

Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR

8:30am

8-K

EX-99.1

qz7m1j

4 Dec 19

Regulation FD Disclosure

8:10am

8-K

EX-99.1

qdzx1jldqjmjma

1 Nov 19

Regulation FD Disclosure

8:00am

8-K

EX-99.1

yjceqa0gq2o4vi0h29

3 Oct 19

Regulation FD Disclosure

8:01am

8-K

EX-99.1

shvkrzo y2ethfo7mk7

5 Aug 19

Regulation FD Disclosure

5:20pm

8-K/A

EX-99.1

3tuctcbha4 cu0

13 May 19

Departure of Directors or Certain Officers

5:28pm

8-K

EX-99.1

5mqlgt9lldl l0nbx

13 May 19

Departure of Directors or Certain Officers

8:00am

8-K

EX-99.1

krjjj376ct25at2u

7 Jan 19

Departure of Directors or Certain Officers

7:31am

8-K

EX-99.1

eug4moo0ot2 ob3q

28 Nov 18

Regulation FD Disclosure

8:00am

8-K

EX-99.2

nnaetntzptw5xr

17 Oct 18

Proteostasis Therapeutics Announces Positive Preliminary Results from

4:30pm

8-K

EX-99.1

2hib7wykirv74

3 Oct 18

Regulation FD Disclosure

8:01am

8-K

EX-99.1

dl6f15zxjolkx85t72

26 Jul 18

Regulation FD Disclosure

7:59am

8-K

EX-99.2

w2bwhg74e bxh8fxgy

6 Jun 18

Proteostasis Announces Positive Data from Ongoing Phase 1 Study ofPTI-801 in Cystic Fibrosis Patients on Background Orkambi® Therapy

4:11pm